MK-677 (Ibutamoren) Satisfaction Trends Over Time: What Users Actually Report

MK-677, also sold or discussed under the name ibutamoren, is an oral, non-peptide growth hormone secretagogue that activates the ghrelin receptor. It is not FDA-approved for any indication, is not a controlled substance, and is distributed through research-chemical vendors rather than pharmacies. It should not be confused with injectable growth hormone or with peptide GH secretagogues such as ipamorelin or CJC-1295, which have different administration routes and pharmacokinetics.

MK-677 (ibutamoren) is an oral ghrelin-receptor agonist that raises growth hormone and IGF-1 for roughly 24 hours per dose. A 12-month trial of 25 mg daily in adults reported sustained IGF-1 elevation of approximately 40 percent versus placebo (Murphy et al., 1998), but no published trial has measured subjective satisfaction with a validated instrument. Online reports of sleep, appetite, and body-composition changes therefore reflect a self-selected population sharing anecdotes, not a controlled outcome measure, and the two should not be conflated when deciding whether to start or continue use.

The useful question for a prospective or current user is not "does MK-677 work" in the abstract. It is which specific effects have trial support, which are plausible extrapolations from that trial support, and which are pattern-matched from forum anecdotes with no independent verification. Those three categories point to different levels of confidence and different next steps.

What the pharmacology predicts, and what it does not

MK-677 stimulates growth hormone release from the pituitary and raises IGF-1 through ghrelin receptor activation. The 1998 Murphy trial, the most cited controlled data on this compound, followed adults on 25 mg daily for 12 months and found sustained IGF-1 elevation without evidence of receptor desensitization (Murphy et al., 1998). That trial is the strongest available evidence anchor for this drug, but it was not designed to measure satisfaction, sleep quality, or body composition using validated patient-reported outcome tools.

This IGF-1 increase is real but moderate. Therapeutic injectable growth hormone at 0.4 to 0.8 mg/day typically raises IGF-1 by a larger margin than oral ibutamoren does. That gap in magnitude helps explain a consistent pattern in user reports: real but modest effects on sleep, recovery, and body composition rather than dramatic transformation, regardless of how the compound is marketed online.

Ghrelin receptor activation also drives appetite stimulation directly. This is not an incidental side effect that disappears with the right routine. It is the same receptor pathway responsible for hunger signaling, and forum reports of unusually strong or "relentless" hunger are consistent with that mechanism.

Weeks one through four: why early reports run favorable

The most consistently reported early benefit across Reddit communities (r/sarms, r/PEDs, r/Peptides) and bodybuilding forums is improved sleep, often described within the first three to seven days. This is physiologically plausible: endogenous GH secretion is closely tied to slow-wave sleep (Van Cauter et al., 1998), and ghrelin receptor activation interacts with that same axis. This link is established background physiology, not proof that MK-677 improves sleep architecture in a clinically measured way, since the cited work does not test ibutamoren directly.

Appetite increase also appears within days and is widely reported. Users who are trying to gain weight often welcome it; users attempting a caloric deficit frequently describe it as the main obstacle to continued use. Mild water retention, described most often in the face and hands, and subjective improvements in skin and nail quality are also common early reports. Negative reports in month one are comparatively rare in these communities, aside from occasional morning lethargy or hand tingling.

Months two through four: why satisfaction commonly declines

By the second month, forum tone shifts in a fairly consistent direction. Sleep benefits are described as persisting but no longer novel. Water retention is reported more frequently and more negatively, sometimes described as facial puffiness, particularly at doses above 15 mg daily. Elevated GH is known to increase sodium and water retention through renal tubular mechanisms in a dose-dependent way (Møller and Jørgensen, 2009), which is consistent with, though not proof of, what forum users describe.

Independent review platforms such as Drugs.com carry too few MK-677 ratings, often well under a hundred per year, to support precise satisfaction-score trends, and any specific numeric average from those platforms should be treated as unverifiable rather than data. What can be said directionally, based on the volume and tone of forum posts, is that complaints about appetite and water retention become more frequent in months two through four, while complaints about lack of perceived effect remain comparatively rare. In other words, the drop in enthusiasm tracks side-effect burden more than it tracks a sense that the drug "stopped working."

A recurring theme in long-running forum threads is that users feel the drug is doing something (better sleep, better joint comfort, fuller muscles) while simultaneously finding the appetite and water-retention burden difficult to sustain. This pattern is described repeatedly across independent posts rather than sourced to any single verifiable quotation.

Fasting glucose is a genuine safety concern with GH secretagogues, since growth hormone can impair glucose regulation in some individuals. Anyone monitoring bloodwork on MK-677 should watch fasting glucose trends and discuss any sustained rise with a clinician rather than interpreting it alone.

The six-month point: who continues and who stops

By month six, the population posting about MK-677 has visibly self-selected. Informal forum polls on r/sarms and r/PEDs, typically drawing well under a couple hundred respondents, suggest that a substantial share of people who start MK-677 have discontinued by this point. The exact proportion is not independently verifiable and should not be quoted as a precise statistic; it is a directional pattern visible across multiple threads, not a measured rate.

Users who report stopping most often cite three overlapping reasons: appetite that feels unmanageable, concern about metabolic effects such as glucose changes, and a sense that body composition changes did not justify the side-effect burden. A smaller group cites cost or inconsistent product quality, which is a reasonable concern given that MK-677 is sold through unregulated research-chemical channels with no standardized third-party testing requirement.

Users who report continuing past six months tend to describe lower doses (10 to 15 mg rather than 25 mg), bedtime-only dosing, and prioritizing sleep and recovery over dramatic body composition change as their goal. Some describe cycling on and off in an attempt to manage water retention; no clinical trial has tested whether cycling changes outcomes, so this remains an unverified practice rather than an evidence-based recommendation.

The clearest controlled body-composition data available comes from a separate short trial in obese adults: two months of MK-677 at 25 mg daily increased fat-free mass by roughly 3 kg versus placebo (Svensson et al., 1998). That population and dose do not necessarily generalize to healthy adults using lower doses for aesthetic or recovery goals, but the magnitude is a useful anchor: it points to a modest recomposition effect, consistent with forum descriptions of "subtle" rather than dramatic change, and inconsistent with more aggressive claims sometimes seen in marketing content.

How satisfaction differs by the reason someone started

Reported satisfaction differs noticeably by goal. Users citing sleep as their primary reason for use report the most consistent and durable satisfaction; the sleep-GH relationship is biologically plausible and the benefit is reported early and repeatedly. Users citing muscle growth as the primary goal report the least satisfaction on average, likely because the anabolic magnitude of oral ghrelin-receptor agonism is small relative to anabolic steroids or higher-dose injectable GH.

Recovery and joint comfort fall in between. Growth hormone has a documented role in collagen synthesis and connective tissue repair (Doessing et al., 2010), and users over roughly 35 frequently report improved joint comfort and between-session recovery. These effects are harder to quantify than weight or visible muscle, which may be why users describe them in more measured language than the early sleep and appetite reports.

Anti-aging-oriented users, who tend to favor the lowest doses (5 to 10 mg), report the flattest satisfaction curve overall: modestly positive without the sharp early peak or the pronounced mid-cycle decline seen in bodybuilding-focused users.

Why the online satisfaction data should be read cautiously

Every satisfaction pattern above comes from self-selected posting, and that limitation changes how it should be used. People who post on Reddit and bodybuilding forums skew toward younger men interested in performance enhancement, skew toward higher doses, and are more likely to post when they hold a strong opinion than when their experience is unremarkable. Research on online health communities more broadly finds that extreme experiences tend to be overrepresented relative to a full population's actual distribution of outcomes (Salzmann-Erikson and Sjödin, 2014), a caution worth carrying into any reading of MK-677 forum sentiment even though that specific study does not examine MK-677.

No published trial has measured MK-677 user satisfaction with a validated patient-reported outcome instrument. Tolerability data and adverse-event tallies from trials describe what happened physiologically; they do not establish how satisfied trial participants felt with their results, and forum data cannot substitute for that missing measurement.

What bloodwork trends suggest, and what remains uncertain

Users who track labs provide a more objective, though still informal, lens on MK-677 over time. The Endocrine Society's clinical practice guideline on adult GH management recommends monitoring IGF-1, fasting glucose, and HbA1c in patients on GH-axis therapies (Molitch et al., 2011); that guideline addresses supervised GH deficiency treatment, not self-directed MK-677 use, but the same monitoring logic is reasonable for anyone altering their GH-IGF-1 axis outside clinical supervision.

In the 12-month Murphy trial, fasting glucose rose modestly (about 0.3 mmol/L) at 25 mg daily. Forum-reported bloodwork trends describe similar-direction changes in glucose and IGF-1 with continued use, but the exact magnitude and timing reported informally online have not been independently verified and vary widely between individuals, so specific percentage or mg/dL figures drawn from forum posts should not be treated as reliable data.

Prolactin elevation is reported by a subset of users, more often at higher doses. This is mechanistically plausible: ghrelin receptor activation can modestly stimulate prolactin release in some individuals (Broglio et al., 2003). Users who find elevated prolactin on labs frequently reduce dose or discontinue, which likely contributes to mid-cycle attrition, though the exact contribution cannot be quantified from available data.

When self-monitoring is not enough

Fasting glucose that rises and stays elevated, new or worsening numbness and tingling, unexplained vision changes, joint swelling with pain, or symptoms of high prolactin (reduced libido, unexpected nipple discharge) are reasons to stop use and seek clinical evaluation rather than waiting out the cycle. MK-677 has no established safe self-monitoring protocol, and anyone with diabetes, prediabetes, a history of hormone-sensitive tumors, or active cancer should not use it outside clinical supervision, if at all.

Evidence boundary: what is established, what is plausible, what is not

Established by controlled trial data: MK-677 at 25 mg daily raises IGF-1 by roughly 40 percent and sustains that elevation over 12 months without apparent desensitization (Murphy et al., 1998); a separate two-month trial in obese adults found a roughly 3 kg fat-free mass increase versus placebo at the same dose (Svensson et al., 1998); fasting glucose rose modestly in the 12-month trial.

Plausible but not directly tested in MK-677 users: that ghrelin-receptor-driven GH pulses improve subjective sleep quality; that GH-mediated water retention explains reported facial puffiness; that GH's role in collagen synthesis explains reported joint comfort; that prolactin elevation contributes to discontinuation.

Not established: the true long-term discontinuation rate among MK-677 users; whether dose cycling changes outcomes; whether lower doses meaningfully change body composition results; and how satisfied representative (non-self-selected) users actually are, since no validated satisfaction instrument has been applied to this drug.

Evidence-Review Framework: Separating What Was Reported From What Was Shown

Use this framework before treating any online claim about MK-677 as a reason to start, continue, or change a dose.

Next decision point: if you are relying on a claim from the bottom two rows to decide whether to start, continue, increase dose, or stop, that claim needs independent verification (bloodwork, a clinician conversation, or a controlled source) before it should change your behavior. Claims from the top two rows can inform expectations but still do not establish personal safety or effectiveness, since neither trial measured satisfaction or long-term use beyond 12 months.